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Abstract
Background: IQ deficits are linked to even mild obstructive sleep apnoea (OSA) in children. Although OSA is
commonly first diagnosed in the pre-school age group, a randomised trial is still needed to assess IQ outcomes
after adenotonsillectomy in the pre-school age-group. This randomised control trial (RCT) will primarily determine
whether adenotonsillectomy improves IQ compared to no adenotonsillectomy after 12 months, in preschool
(3–5 year-old) children with mild to moderate OSA.
Methods: This protocol is for an ongoing multi-centred RCT with a recruitment target of 210 subjects (105 in
each arm). Children age 3–5 years with symptoms of OSA, are recruited through doctor referral, at the point
of referral to the Ear Nose and Throat (ENT) services. Screening is initially with a questionnaire (Paediatric
Sleep Questionnaire, PSQ) for symptoms of obstructive sleep apnoea (OSA). Where questionnaires are positive
(suggestive of OSA) and ENT surgeons recommend them for adenotonsillectomy, they are invited to participate in
POSTA. Baseline testing includes neurocognitive testing (IQ and psychometric evaluation with the neuropsychologist
blinded to randomisation) and overnight polysomnography (PSG). Where the Obstructive Apnoea-Hypopnea Index
(OAHI) from the PSG is <10/h per hour, consent for randomisation is sought; children with severe OSA
(OAHI ≥ 10/h) are sent for immediate treatment and excluded from the study. After consent is obtained,
participants are randomised to early surgery (within 2 months) or to surgery after a usual wait time of
12 months. Follow-up studies include repeat neurocognitive testing and PSG at 12 (with the waiting list
group studied before their surgery) and 24 months after randomisation. Analysis will be by intention to treat.
The primary outcome is IQ at 12 months’ follow-up.
Discussion: If IQ deficits associated with OSA are reversible 12 months after adenotonsillectomy compared to
controls, future clinical practice advise would be to undertake early surgery in young children with OSA. The study
could provide data on whether a window of opportunity exists for reversing IQ deficits linked to OSA in the pre-school
age-group.
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Background
Children with upper airway obstruction in sleep (ob-
structive sleep apnea, or OSA) may display repetitive,
discrete episodes of airway obstruction associated
with intermittent desaturation and arousal. However,
they frequently also demonstrate long periods of
partial airway obstruction associated with snoring, in-
creased work of breathing and normal gas exchange
in addition to the discrete events, or as their only
expression of the disease.
Snoring reportedly affects 8–12% of children while
1–3% have OSA with discrete respiratory events [1].
Thus, even at its lowest prevalence, around 1 child in
every primary school classroom has OSA, equating to
80,000 affected children in Australia and 16,000
children in New Zealand [2]. Although snoring and
OSA are common across the childhood age-range,
studies specific to the pre-school age group are vital.
The first presentation of OSA is often in this age
group, when the lymphoid tissue of the adenoids and
tonsils is at its largest relative to the bony skeleton
of the airway, thus compromising the upper airway
size [3]. Adenotonsillar enlargement is the common-
est treatable element of OSA in children and adeno-
tonsillectomy (AT) constitutes the primary treatment
intervention.
Polysomnography (PSG) is the standard investiga-
tion used to detect the presence and severity of OSA
[4]. PSG studies provide an audio-visual assessment
of obstruction and a documentation of the frequency
of apneic events; defined as the number of obstruct-
ive apnoea & hypopnea events that occur per hour
of sleep time. PSG outcomes thus provide the index
of events per hour (OAHI), the severity of blood gas
disturbances (hypoxia and hypercapnia), and the fre-
quency of arousals. In the pediatric literature the se-
verity of airway obstruction is then classified from PSG
as on the basis of the obstructive apnoea-hypopnea index
(OAHI).
Neurocognitive associations with OSA
Recent studies show that snoring or mild OSA are
associated cognitive and behavioral deficits in
school-age children [5–14]. The mechanism of the
association is not clear, and studies have examined
associations with hypoxia, sleep fragmentation, and lack of
cerebral blood flow adaptation as likely candidates
[15–18]. Most human studies pertaining to recovery of
neurocognitive function examine sequelae of traumatic or
acute brain injury. Importantly, a number of those studies
show that younger children generally have less capacity to
compensate for brain injury than older children [19]. In
contrast, some small studies suggest greater potential for
recovery of specific neurocognitive processes in younger
children [20].
To date, a substantial amount of the literature per-
taining to neurocognition in children with OSA has
come from studies in school-age children. The biggest
cognitive impact of OSA is on children’s executive
function. The development of the components of
executive function is rapid in the age-range of 3–8
years, but continues through childhood and adoles-
cence and is aligned with growth spurts and myelin-
ation in the frontal lobes [21]. Specific links have
been suggested amongst sleep, behavioral problems,
and executive function because of the prolonged
developmental time frame of executive function in
childhood, including the potential for there being a
critical period of development [22]. Limited know-
ledge regarding the effects of age at the time of brain
injury on subsequent IQ recovery means that results
from studies of OSA in school-age children cannot be
confidently extrapolated into the pre-school age
group. Therefore, pre-school children are a vitally import-
ant group in which to investigate the adverse effects
of OSA.
Changes after treatment of OSA
The Childhood Adenotonsillectomy trial (CHAT) is a
published randomized controlled trial in children evalu-
ating IQ outcomes after adenotonsillectomy. Children in
that study were school-age aged 5–9 years (n = 464),
with 7 month follow up post intervention [23]. That
study found no effect of early AT on attention or execu-
tive function as measured by neuropsychological testing.
However the positive impacts of surgery included re-
duced symptoms and improved behavior, quality of life
and PSG findings, so the authors concluded that the
study provided evidence of the beneficial effects of early
AT [23]. An editorial accompanying the publication of
the CHAT study suggested that studies now need to
focus on children at a younger age and with longer
follow-up to evaluate whether IQ deficits are at all
reversible [24].
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Aims
The POSTA (Pre-school OSA Tonsillectomy Adenoidect-
omy study) is a randomized, controlled trial of adenotonsil-
lectomy in pre-school age children, with mild to moderate
OSA, designed to evaluate neurocognitive outcomes after
early adenotonsillectomy compared to watchful waiting,
with a 12-month follow-up. Subjects will be assessed at
baseline and again 12 months after randomization. Subjects
randomized to the control group will have surgery follow-
ing their 12 month follow-up assessment (approximating
the average delay to surgery in Australia for children with
this severity of OSA). Subjects randomized to intervention
will have AT within 2 months of randomization. The spe-
cific aim is to determine whether AT improves IQ in pre-
school (3.0–5.0 year-old) children with mild to moderate
OSA in a group who undergo early AT compared to those
with no ATafter 12 months. The design will allow us to test
the principal hypothesis that IQ benefits will be demon-
strable 12 months after surgery as opposed to no surgery in
the pre-school age-group. Table 1 shows the primary and
secondary outcomes to be measured.
Design
Overview of the study design
Pre-school age children (3.0–5.0 year-old) with a history of
snoring will be contacted at the point of referral. The
Pediatric Sleep Questionnaire (PSQ) will be used to screen
for symptoms of OSA [25]. Children with a questionnaire
score suggestive of OSA will be eligible for overnight sleep
studies to classify the severity of their disease. Those with
mild to moderate OSA (obstructive respiratory event index
<10 per hour) are eligible for inclusion. Those with severe
OSA (10 per hour) will be sent for immediate treatment
and excluded. Recruited subjects will proceed to neurocog-
nitive (IQ) testing and will then be randomized to either
immediate or routine surgical waiting times. The neurocog-
nitive tests (see details below) will apply to all participating
children at baseline, then at 12- and 24-month follow-up. A
routine surgical wait time for adenotonsillectomy means
surgery 12 months after randomization, while early surgery
will occur within 2 months of randomization. All children
will have repeat neurocognitive testing 12 months after
their randomization.
Recruitment strategy
Families referred to the hospital for adenotonsillectomy
because of a history suggestive of OSA will be approached
by mail for participation in this study. A letter, including
the Pediatric Sleep Questionnaire (“PSQ”) questionnaire
for OSA [25], will be sent to the families with a postage
paid return envelope. Children with positive answers to
≥33% of the 22 question-items are considered to have a
questionnaire diagnosis of OSA and will be invited to
undergo overnight polysomnography (PSG, see below for
details) to define the severity of their OSA. Questionnaire
screening will ensure that children having PSG have high
probability of OSA as this questionnaire has specificity of
0.87 for OSA in a general pediatric setting. After PSG chil-
dren with an OAHI < 10 events/h will proceed to baseline
testing while those with an OAHI >10 will require early
clinical intervention and exclusion from further study.
Exclusion criteria
Children with medical conditions known to affect neuro-
cognitive development (including hearing loss of >35 DB),
previous tonsillectomy or airway surgery, high-risk genetic
and craniofacial syndromes, identified neurodevelopmental
conditions, cyanotic heart disease or previous cardiopul-
monary bypass, and conditions that preclude neurocogni-
tive testing or that preclude adenotonsillectomy will be
excluded. Children with severe OSA (OAHI >10/h on
sleep study) will also be excluded because they need to
proceed to treatment to avoid morbidity from ongoing
OSA. This group also has higher post-operative complica-
tion rates [26, 27]. Table 2 shows the list of inclusion and
exclusion criteria.
Testing
Neurobehavioural (IQ) assessment after a hearing test
(see exclusion criteria), PSG and medical review will be
undertaken at baseline prior to randomization and re-
peated 12 months after randomization. Baseline testing
also includes standardized history and medical examin-
ation and behavioral testing. The medical review will in-
clude family and personal histories of atopy, visual
grading of tonsil size, measurement of body weight,
height and calculated body mass index (BMI), and evening
and morning blood pressure.
Method of randomization
After completing initial questionnaire, sleep study and IQ
assessments, children will be centrally randomized either
Table 1 Primary and secondary outcomes
Primary Outcome: Intellectual ability (IQ) as determined by the
Woodcock-Johnson III (WJ-III) Test of Cognitive Abilities
Secondary Outcomes:
• Behavioral parameters (PRS-BASC-II)
• Executive Function (BRIEF-P)
• Parental Stress (Parental Stress Index)
• Polysomnography (PSG) parameters
• Sleep Symptoms (Pediatric Sleep Questionnaire- PSQ)
• Anthropometry: change in height, weight, and BMI percentiles
• Blood Pressure: Mean arterial pressure
• Audiology
• Quality of life
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to immediate surgery or to remain as waiting list controls.
Study center and severity of OSA may all influence study
outcomes. To avoid imbalance between the groups, these
prognostic factors will be used for stratified randomization
with OSA classified as < 5 events/h or > 5 events/h by
center. To avoid small cell sizes we will implement a
minimization algorithm to ensure that randomization
groups are balanced for the stratifying variables. Central-
ized randomization is through the Children’s Hospital at
Westmead. Each patient will be assigned a unique trial
number that will be used for recording all their data.
Protocols will be standardized between centers, including
sleep study analysis, IQ testing, and surgical procedures.
Intervention will comprise adenotonsillectomy within
2 months of the assignment date. All children will undergo
complete extra-capsular tonsillectomy and adenoidectomy,
regardless of the size of the adenoids. The adenoidal bed
will be visualized at the end of the procedure, to ensure the
adenoidectomy is satisfactorily complete. It has been agreed
that diathermy for adenoids is acceptable.
The main retention strategy will be 2-monthly phone
contact with participant families, during which 5 ques-
tions will be asked about the child’s health.
Setting
The group designing the study included Paediatric Sleep
Physicians and ENT surgeons representing all major Aus-
tralian Paediatric centres. The study is taking place in three
Australian Children’s hospitals and will take subjects from
their referring centres.
Sample size and power of the study
The standard deviation of IQ over 1 year is estimated to
be approximately 8 points [28, 29]. The study aims to
detect a difference in change in IQ of at least 4 points
(0.5 standard deviation units)1 year after the baseline
assessment. To detect this difference, with a power on
0.9 and a significance of 0.05 we will require 86 children
in each group or 172 in total.
In order to retain the intended power of the study,
the sample size will need to be increased to 94 in
each group or 188 in total (estimated by Pocock
method in Power analysis and sample size (PASS)
Statistical Software, Utah 2008). Assuming that 90%
of randomised subjects have their IQ assessed at
follow-up, we plan to randomise 210 subjects, that is,
105 in each group.
Recruitment
The final recruitment target is 210. We have been able
to recruit 22 children in one centre over a 12 month
period and estimate that three study centres will complete
recruitment in 2.5 years, and follow-up all subjects in
3.5 years. This rate of recruitment will require that ap-
proximately one child per month have immediate surgery.
During the period while recruitment and follow-up are
occurring concurrently, the requirement is for 4 PSG
studies per month at each centre (2 new and 2 follow-
up if all of the new recruits in any 1 month are
eligible).
Specific assessment procedures
Neurobehavioural and neurocognitive testing
A qualified psychologist will conduct neurobehavioural
and neurocognitive testing on each child at each assess-
ment. The major outcome measure will be intellectual
ability as determined by the Woodcock-Johnson III
(WJ-III) Test of Cognitive Abilities [30]. Measurement
bias will be minimized by ensuring that the psycholo-
gists conducting the psychological assessments at
follow-up are blinded to treatment group allocation.
Participants will be coached to avoid disclosure.
Intellectual ability will be estimated by administering
the seven core subtests of the WJ III: Verbal Compre-
hension, Visual-Auditory Learning, Spatial Relations,
Sound Blending, Concept Formation, Visual Matching
and Numbers Reversed. The composite of these subtests
is the measure of IQ, termed GIA in the WJ III.
Amongst candidate IQ tests, the WJ-III is unique in per-
mitting testing over the proposed age range (i.e., 3.0–
6.9y inclusive) using the same test items at different age
bands. In addition to estimating general intellectual
ability, the core subtests of the WJ III can be used to
examine more specific cognitive skills that may be sensi-
tive to sleep disruption. In the 3–6 y age range, specific
cognitive abilities measured by the core subtests include:
language development and verbal knowledge, complex
thinking processes (long term retrieval of information,
Table 2 POSTA eligibility and exclusion criteria
Inclusion Criteria:
1. Children aged 3–5 years at the time of primary assessment for
evaluation of snoring
2. Deemed suitable for adenotonsillectomy on surgical evaluation
3. Confirmed on PSG to have mild-moderate OSA, defined as
OAHI < 10 events/h
Exclusion Criteria:
1. Medical conditions known to affect neurocognitive development
(including hearing loss >35DB)
2. Previous tonsillectomy or airway surgery
3. High risk genetic and craniofacial syndromes
4. Previously identified neurodevelopmental conditions
5. Cyanotic heart disease or previous cardiopulmonary bypass
6. Conditions that preclude neurocognitive testing or that preclude
adenotonsillectomy
7. Confirmed on PSG to have severe OSA, define as OAHI >10/h
PSG polysomnography, OAHI obstructive apnoea hyponoea index
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visual-spatial thinking, auditory processing and fluid
reasoning), and more automatic thinking processes
(short term memory and processing speed). Two
additional WJ III subtests will be used to provide fur-
ther assessment of attention and executive function:
Retrieval Fluency and Picture Recognition. The WJ-III
is normed on a sample of >8100 US children and is
reported to have high test-retest reliability, high internal
consistency, strong convergent validity and a robust factor
structure [30]. WJ-III testing time is estimated to be
30–50 min.
Behavioral parameters and fluid skills incorporated in
executive function are deleteriously affected by OSA.
These will be further tested using the Parent Rating
Scale of the Behavioral Assessment System for Children-
II (BASC-PRS) [31] and the Behavior Rating of Executive
Functioning (BRIEF-P) [28].
The BASC-PRS contains 160 items and uses a
four-choice response format. In the 3-6y age range,
the BASC-PRS provides information about a range of
areas of functioning including emotional and psycho-
logical functioning (e.g., anxiety, depression), behav-
ior (e.g., aggression, activity levels), social skills and
interaction, attention and activities of daily living. It
is reported to possess high test-retest reliability, high
internal consistency and a robust factor structure
[31]. The BRIEF-P consists of 63 items and uses a
three-choice response format and provides informa-
tion about executive function in everyday settings in-
cluding skills such as behavioral and emotional
control, planning and organization, attention and in-
formation processing. It is reported to possess high
internal consistency and reliability, good convergent
and discriminant validity and a robust factor struc-
ture [28]. The PRS is estimated to take 15 min and the
Brief-P 15 min for parents/caregivers to complete.
Finally, parent stress is associated with sleep and
behavior difficulties in children so this will be assessed
using the Parenting stress Index (PSI) [32]. The PSI
consists of 120 questions and yields a Total Stress Score,
a Child Domain score, a Parent Domain score and a Life
Stress score. Child characteristics are measured on 6
subscales: Distractibility, Hyperactivity, Reinforces Par-
ent, Demandingness, Mood and Acceptability. Parent
personality and situational variables are measured on 7
subscales: Competence, Isolation, Attachment, Health,
Role Restriction, Depression and Relationship with
Spouse. The PSI has satisfactory internal consistency,
robust test-retest reliability [32]. The PSI takes 20–30
min to complete.
The maximum testing time (including breaks) for neuro-
behavioural and neurocognitive testing is estimated to be
2 h, but 4 h will be allowed for each child for the full test-
ing battery.
Polysomnography (PSG)
Each participant identified by questionnaire will undergo
full overnight sleep studies using standard clinical
pediatric techniques and analyses. At each acquisition
point, the sleep study results will only be included if they
capture a minimum of 4 h recording time and at least
2 cycles of REM sleep; if these are not obtained, a repeat
PSG will be undertaken.
Total sleep time and the obstructive apnoea hypop-
nea index (AHI) defined as the total number of
obstructive apnoeas, mixed apnoeas, and obstructive
hypopneas per hour of sleep will be calculated. PSG
will be scored using American Academy of Sleep
Medicine (AASM) 2007 guidelines [33], as these guide-
lines were current at the time of study design and its
commencement.
Sleep study concordance
As sleep studies will be carried out in 3 different sleep
laboratories, a maximum of two experienced sleep tech-
nologists will be solely responsible for analysis of the
PSG studies in each center. Analysis criteria have been
agreed upon and those involved in analyzing studies will
meet regularly to evaluate studies and ensure concord-
ance. No published data exists on multi-center trial con-
cordance for pediatrics.
The severity of OSA is defined by the number of ob-
structive apnoea & hypopnea events that occur per hour
of sleep time expressed as the index of events per hour
(OAHI). Standard diagnostic categories for pediatric
OSA will be used and are: Primary Snoring <1 event/h;
mild OSA 1–5 events/h; moderate OSA 5–10 events/h;
and severe OSA >10 events/h [34]. Severe OSA experience
nocturnal respiratory failure and severe desaturations, and
there is clinical imperative for them to receive the benefi-
cial effects of adenotonsillectomy [34–36].
Data collection & storage
This study will generate a significant amount of data,
due to the large amounts of data points per test and the
2 time points of study. The database for POSTA has
been custom-designed to allow handling of this data. It
is a secure centralized web-based system that allows
transfer of data directly from source for many of the
data points. Each study site can upload information
directly into the centralized system, ensuring clean and
compatible data for analysis. The direct export of PSG
and neurocognitive data into this central database will
minimize errors that could otherwise occur from manual
data entry. Summary data can be generated and exported
to relevant statistical packages according to requirements
for data analysis (http://www.postastudy.org).
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Discussion
Management of recruitment challenges
Acknowledged challenges of clinical trials include parental
(participant) perceptions of a randomised treatment, in-
cluding surgical procedures [37]. Our protocol, requiring
repeat sleep studies and assessments, is challenging for
young families where younger siblings are common, and
this may delay recruitment or lead to high dropout rates.
The protocol has been standardised across sites, but some
disparities in practice will inevitably evolve across different
sites. For example, in Sydney children with uncomplicated
adenotonsillectomy ATs are increasingly likely to have sur-
gery performed in secondary, rather than tertiary hospi-
tals. Informing the relevant departments and staff, and
obtaining ethical approval for recruitment from these sites
can take considerable time and families from those loca-
tions have considerable additional travel requirements if
they choose to participate because paediatric sleep facili-
ties are only available at the tertiary centres. Disruption to
the protocol also occurred when one hospital move to
new facilities, a factor which may occur again.
The primary outcome of follow-up at 12 months is
our priority and we are confident we can get follow-up
of 180 children (90 in each arm) with current funding.
Outcomes and significance
As demonstrated in the background literature, the clinical
questions being addressed by this study are of national
and international significance. Large, prospective random-
ized trials are required if we are to measure, with accuracy,
whether early deficits in IQ resulting from OSA are re-
versible in the pre-school age-group. This study will also
help determine whether the timing of adenotonsillectomy
needs to be changed in pre-school children with mild to
moderate OSA.
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